Form 4: Roivant Sciences Director Reports Routine Share Award and Tax-Related Sale

Roivant Sciences Director James C. Momtazee reported the acquisition of 1,201 common shares as an award and the disposition of 241 shares for tax withholding purposes, resulting in a net beneficial ownership of 96,670 shares.

Summary

• James C. Momtazee, a Director of Roivant Sciences Ltd. (ROIV), reported changes in his beneficial ownership of common shares.
• On July 17, 2025, Momtazee acquired 1,201 common shares at a price of $0 per share. This acquisition was an award under the Issuer's Non-Employee Director Compensation Plan and was fully vested upon grant.
• On the same date, Momtazee disposed of 241 common shares at a price of $11.65 per share. This disposition was a "net settlement" by Roivant Sciences to satisfy applicable tax withholding obligations related to the vesting and settlement of shares from the Non-Employee Director Compensation Plan.
• Following these transactions, James C. Momtazee's direct beneficial ownership of Roivant Sciences common shares is 96,670.

Sentiment

Score: 5

Explanation: Neutral. This is a routine insider transaction related to director compensation and tax withholding, which is neither significantly positive nor negative for the company's outlook.

Positives

• Director James C. Momtazee received an award of 1,201 common shares, indicating ongoing compensation for his role.
• The shares acquired were fully vested as of the grant date, providing immediate ownership.

Negatives

• A portion of the awarded shares (241 shares) was sold to cover tax withholding obligations, reducing the net increase in beneficial ownership.

Future Outlook

The document does not provide forward-looking statements or guidance beyond the reporting of past transactions.

Industry Context

This Form 4 filing reflects routine insider compensation practices within the biotechnology or pharmaceutical industry, where equity awards are a common component of director compensation. It does not provide broader industry trends or competitive analysis.

Comparison to Industry Standards

• The compensation structure involving equity awards and net settlement for tax purposes is a standard practice across many publicly traded companies, including those in the biotechnology sector.
• While specific comparable companies or projects are not detailed in this filing, similar compensation plans are observed at peers like Moderna (MRNA), Pfizer (PFE), or Johnson & Johnson (JNJ) for their non-employee directors, though the specific number of shares and values would vary based on company size, performance, and compensation policies.

Corporate Governance

Stakeholder Impact

• Shareholders: The director's increased beneficial ownership (net of tax sales) aligns his interests with shareholders. The sale for tax purposes is a standard event and does not indicate a lack of confidence.

Key Dates

Recommendation

Keywords

Roivant Sciences, ROIV, Form 4, Insider Transaction, Director Compensation, Share Ownership, Equity Award, Tax Withholding, Beneficial Ownership